TY - JOUR
T1 - Spectrum of mutations in PTPN11 and genotype - Phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome
AU - Musante, Luciana
AU - Kehl, Hans G.
AU - Majewski, Frank
AU - Meinecke, Peter
AU - Schweiger, Susann
AU - Gillessen-Kaesbach, Gabriele
AU - Wieczorek, Dagmar
AU - Hinkel, Georg K.
AU - Tinschert, Sigrid
AU - Hoeltzenbein, Maria
AU - Ropers, Hans Hilger
AU - Kalscheuer, Vera M.
N1 - Funding Information:
The authors thank the patients and their families, and the patient group Noonan-Kinder eV Deutschland for their interest in our study. We also thank the clinicians and physicians for sending blood samples. B Royer-Pokora, T Goecke, S Wudy and B Göldner are thanked for their support. Thanks to K Hoffmann, U Fischer, H Madle and S Freier for technical assistance. This grant was supported by DHGP grant no. 01KW99087 to H-H Ropers.
PY - 2003/2/1
Y1 - 2003/2/1
N2 - Noonan syndrome (NS) is a relatively common, but genetically heterogeneous autosomal dominant malformation syndrome. Characteristic features are proportionate short stature, dysmorphic face, and congenital heart defects. Only recently, a gene involved in NS could be identified. It encodes the non-receptor protein tyrosine phosphatase SHP-2, which is an important molecule in several intracellular signal transduction pathways that control diverse developmental processes, most importantly cardiac semilunar valvulogenesis. We have screened this gene for mutations in 96 familial and sporadic, well-characterised NS patients and identified 15 different missense mutations in a total of 32 patients (33%), including 23 index patients. Most changes clustered in one exon which encodes parts of the N-SH2 domain. Five of the mutations were recurrent. Interestingly, no mutations in the PTPN11 gene were detected in five additional patients with cardio-facio-cutaneous (CFC) syndrome, which shows clinical similarities to NS.
AB - Noonan syndrome (NS) is a relatively common, but genetically heterogeneous autosomal dominant malformation syndrome. Characteristic features are proportionate short stature, dysmorphic face, and congenital heart defects. Only recently, a gene involved in NS could be identified. It encodes the non-receptor protein tyrosine phosphatase SHP-2, which is an important molecule in several intracellular signal transduction pathways that control diverse developmental processes, most importantly cardiac semilunar valvulogenesis. We have screened this gene for mutations in 96 familial and sporadic, well-characterised NS patients and identified 15 different missense mutations in a total of 32 patients (33%), including 23 index patients. Most changes clustered in one exon which encodes parts of the N-SH2 domain. Five of the mutations were recurrent. Interestingly, no mutations in the PTPN11 gene were detected in five additional patients with cardio-facio-cutaneous (CFC) syndrome, which shows clinical similarities to NS.
UR - http://www.scopus.com/inward/record.url?scp=0037300995&partnerID=8YFLogxK
U2 - 10.1038/sj.ejhg.5200935
DO - 10.1038/sj.ejhg.5200935
M3 - Journal articles
C2 - 12634870
AN - SCOPUS:0037300995
SN - 1018-4813
VL - 11
SP - 201
EP - 206
JO - European Journal of Human Genetics
JF - European Journal of Human Genetics
IS - 2
ER -